Germany-based BioNTech AG is to expand its portfolio of individualised therapies beyond cancer to include infectious disease. Under a new collaboration with Pfizer Inc, the two companies will develop messenger RNA-based vaccines for the prevention of influenza.
The agreement involves an initial payment of $120 million to BioNTech plus potential development, regulatory and commercial milestones of up to up to $305 million.